Market Place
Sourcing Support
All News #Library
Biotech
NGM Bio cuts 75% of staff, halts midstage liver disease program
13 May 2025 //
FIERCE BIOTECH
NGM Bio Doses 1st Patient In Ph 2 Study For Hyperemesis Gravidarum
24 Feb 2025 //
GLOBENEWSWIRE
3 months after taking NGM Bio private, VC firm oversees biotech’s $122M series A
17 Jul 2024 //
FIERCE BIOTECH
NGM Bio to Present Two Posters Highlighting of Ongoing Ph 1/2 Trial of NGM707
19 Mar 2024 //
GLOBENEWSWIRE
NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707
09 Jan 2024 //
GLOBENEWSWIRE
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin
13 Nov 2023 //
GLOBENEWSWIRE
NGM Bio Announces Plenary Presentation of Data from Phase 2b Trial of Aldafermin
11 Oct 2023 //
GLOBENEWSWIRE
NGM Bio Announces Presentation of Data from Ph2 Investigator Trial of Aldafermin
08 May 2023 //
GLOBENEWSWIRE
Following clinical setbacks, NGM Bio lays off 33% of staffers as founder departs
06 Apr 2023 //
ENDPTS
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.